Effect of HER2 on prognosis and benefit from peri-operative chemotherapy in early oesophago-gastric adenocarcinoma in the MAGIC trial. [electronic resource]
Producer: 20131219Description: 1253-61 p. digitalISSN:- 1569-8041
- Adenocarcinoma -- drug therapy
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Agents -- therapeutic use
- Antineoplastic Combined Chemotherapy Protocols -- administration & dosage
- Biomarkers, Tumor -- metabolism
- Cisplatin -- therapeutic use
- Combined Modality Therapy
- Epirubicin -- therapeutic use
- Esophageal Neoplasms -- drug therapy
- Female
- Fluorouracil -- therapeutic use
- Humans
- Male
- Middle Aged
- Perioperative Period
- Prognosis
- Receptor, ErbB-2 -- genetics
- Stomach Neoplasms -- drug therapy
- Young Adult
No physical items for this record
Publication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.